CO2020010191A2 - Inhibidores de cd73 - Google Patents

Inhibidores de cd73

Info

Publication number
CO2020010191A2
CO2020010191A2 CONC2020/0010191A CO2020010191A CO2020010191A2 CO 2020010191 A2 CO2020010191 A2 CO 2020010191A2 CO 2020010191 A CO2020010191 A CO 2020010191A CO 2020010191 A2 CO2020010191 A2 CO 2020010191A2
Authority
CO
Colombia
Prior art keywords
inhibitors
pyridazin
dione
pyrimidine
cycloalkyl
Prior art date
Application number
CONC2020/0010191A
Other languages
English (en)
Inventor
Robert Dean Dally
Jennifer Marie Howell
Lawrence Joseph Ii Heinz
Frank George Njoroge
Yan Wang
Paredes Maria Cristina Garcia
Genshi Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2020010191A2 publication Critical patent/CO2020010191A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona 5-[5]-[2-cicloalquil]-6-piridazin-3-il]-1H-pirimidin-2,4-diona, o sales aceptables desde el punto de vista farmacéutico de este, que inhiben la actividad de CD73 y son útiles en el tratamiento contra el cáncer.
CONC2020/0010191A 2018-03-01 2020-08-19 Inhibidores de cd73 CO2020010191A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05
PCT/US2019/019074 WO2019168744A1 (en) 2018-03-01 2019-02-22 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
CO2020010191A2 true CO2020010191A2 (es) 2020-08-31

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010191A CO2020010191A2 (es) 2018-03-01 2020-08-19 Inhibidores de cd73

Country Status (33)

Country Link
US (1) US11028074B2 (es)
EP (1) EP3759096B1 (es)
JP (1) JP6794560B2 (es)
KR (1) KR20200116965A (es)
CN (1) CN111819173B (es)
AU (1) AU2019228473B2 (es)
BR (1) BR112020016066A2 (es)
CA (1) CA3092661C (es)
CL (1) CL2020002158A1 (es)
CO (1) CO2020010191A2 (es)
CR (1) CR20200376A (es)
CY (1) CY1125145T1 (es)
DK (1) DK3759096T3 (es)
DO (1) DOP2020000148A (es)
EC (1) ECSP20052897A (es)
ES (1) ES2909701T3 (es)
HR (1) HRP20220459T1 (es)
IL (1) IL277006B2 (es)
JO (1) JOP20200209A1 (es)
LT (1) LT3759096T (es)
MA (1) MA52413A (es)
MX (1) MX2020009115A (es)
PE (1) PE20210177A1 (es)
PH (1) PH12020551464A1 (es)
PL (1) PL3759096T3 (es)
PT (1) PT3759096T (es)
RS (1) RS63073B1 (es)
SG (1) SG11202008366RA (es)
SI (1) SI3759096T1 (es)
TW (1) TWI702954B (es)
UA (1) UA123890C2 (es)
WO (1) WO2019168744A1 (es)
ZA (1) ZA202004805B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502548A (zh) * 2019-08-29 2022-05-13 伊莱利利公司 Cd73抑制剂的结晶形式
US20210198239A1 (en) * 2019-12-06 2021-07-01 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
TW202206422A (zh) 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
AU2021264550A1 (en) * 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022052886A1 (zh) 2020-09-08 2022-03-17 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN114315839A (zh) * 2020-09-30 2022-04-12 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
US20230399314A1 (en) 2020-11-05 2023-12-14 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Cd73 inhibitor and use thereof
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023169327A1 (zh) * 2022-03-07 2023-09-14 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024006929A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024013206A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Heterocycle compounds for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709660A2 (pt) 2006-04-03 2011-07-19 Glaxo Group Limided derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
TW202227095A (zh) * 2016-01-08 2022-07-16 美商阿克思生物科學有限公司 胞外5'-核苷酸酶之調節劑及其用途
WO2017153952A1 (en) * 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
CR20200376A (es) 2020-10-23
AU2019228473A1 (en) 2020-08-20
KR20200116965A (ko) 2020-10-13
CN111819173B (zh) 2023-06-06
MX2020009115A (es) 2022-11-15
IL277006A (en) 2020-10-29
PE20210177A1 (es) 2021-01-29
PH12020551464A1 (en) 2021-09-01
JOP20200209A1 (ar) 2020-08-30
US11028074B2 (en) 2021-06-08
DOP2020000148A (es) 2020-09-15
JP2020517655A (ja) 2020-06-18
IL277006B2 (en) 2023-03-01
PL3759096T3 (pl) 2022-05-09
CL2020002158A1 (es) 2020-11-13
TW201945002A (zh) 2019-12-01
JP6794560B2 (ja) 2020-12-02
CA3092661C (en) 2022-07-12
WO2019168744A1 (en) 2019-09-06
EP3759096B1 (en) 2022-02-16
RS63073B1 (sr) 2022-04-29
SG11202008366RA (en) 2020-09-29
CA3092661A1 (en) 2019-09-06
BR112020016066A2 (pt) 2020-12-08
AU2019228473B2 (en) 2021-02-25
EP3759096A1 (en) 2021-01-06
ES2909701T3 (es) 2022-05-10
MA52413A (fr) 2021-01-06
TWI702954B (zh) 2020-09-01
UA123890C2 (uk) 2021-06-16
PT3759096T (pt) 2022-03-30
HRP20220459T1 (hr) 2022-05-27
IL277006B (en) 2022-11-01
LT3759096T (lt) 2022-04-11
CY1125145T1 (el) 2024-02-16
DK3759096T3 (en) 2022-03-07
ECSP20052897A (es) 2020-09-30
CN111819173A (zh) 2020-10-23
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
ZA202004805B (en) 2022-01-26

Similar Documents

Publication Publication Date Title
ECSP20052897A (es) Inhibidores de cd73
ECSP19033052A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP19032676A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2018001753A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201600839)
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
CO2018006097A2 (es) Pesticidas azoles bicíclicos sustituídos con heterociclo
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
CO2022000270A2 (es) Inhibidores de enzimas
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ES2970191T3 (es) Formulación que comprende aceite ozonizado en el tratamiento de un tumor
CL2016003271A1 (es) Métodos para tratar infecciones
EA202091821A1 (ru) Ингибиторы cd73
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
MA53225A (fr) Agents inhibiteurs d'ask1